Humanized complement 5a receptor 1 antibodies and methods of use thereof
US12264203B2 · kind B2 · utility
0Cited by
48References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2024 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | May 31, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.